CollPlant (CLGN) Biotechnologies announced the expansion of its agreement with STEMCELL Technologies, a biotechnology company that develops and supplies specialized cell culture media, tools, and services to support research in stem cell biology, regenerative medicine, immunology, and related life sciences. The amended agreement broadens the use of CollPlant’s rhCollagen, extending beyond research applications to include clinical development and commercial-scale manufacturing.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on CLGN:
- CollPlant Secures European Patent for Collagen-Based Formulations
- CollPlant announces European patent allowance
- CollPlant Biotechnologies Announces $3.6 Million Securities Offering
- CollPlant Biotechnologies Secures $3.6 Million in Direct Offering
- CollPlant to sell 1.2M ordinary shares at $3.00 in registered direct offering